LGM Pharma Invests US$6 million to Expand Drug Manufacturing Facility in USA
Introduction:
LGM Pharma plans to invest $6 million in expanding its manufacturing facility in Rosenberg, Texas.
Features:
The expanding manufacturing capacity for liquid, suspension, semi-solid, and suppository drug formulations to meet increasing market demand.
The facility features advanced traceability technology to comply with regulatory requirements and improve product tracking and aligns the Rosenberg site with high manufacturing and quality standards.
The expansion of regulatory compliance ensures adherence to US FDA regulations and cGMP standards for pharmaceutical manufacturing.
These infrastructure Enhancements strengthen quality systems and operational efficiencies at the Rosenberg facility to support Prescription Drug Applications and facilitate the development of 505(b)(2), NDA, and ANDA projects, with ongoing submissions to regulatory authorities.
The expansion reduces reliance on global supply chains by expanding domestic pharmaceutical manufacturing.
Specifications:
| Name | LGM Pharma |
| Type | New Construction |
| Budget | US$6 million |
